Merck & Co., Inc.
Merck Reports Strong Q1 2024 Earnings, Raises Outlook
Summary
Merck & Co., Inc. announced its financial results for the first quarter of 2024, reporting a 9% increase in total worldwide sales to $15.8 billion. The company saw significant growth in its oncology and vaccines segments, driven by KEYTRUDA and GARDASIL/GARDASIL 9 sales. GAAP EPS was $1.87, while non-GAAP EPS was $2.07, including a $0.26 charge for the acquisition of Harpoon. Merck also provided an updated financial outlook for 2024, raising its expected non-GAAP EPS range to between $8.53 and $8.65.
Profitelligence Alerts
Get alerts for MRK
Be first to know when Merck & Co., Inc. files with the SEC.
Filing Categories
Exhibits (2)
Advertisement
About Merck & Co., Inc.
Merck & Co., Inc. is a prominent player in the global pharmaceutical industry. It is primarily focused on the research, development, production, and marketing of drugs and vaccines. Known for its strong emphasis on innovative health solutions, Merck develops treatments and vaccines for a variety of diseases affecting humans and animals. Key areas include oncology, infectious diseases, diabetes, and vaccines, reflecting its commitment to addressing critical health challenges worldwide. The company operates in several strategic regions, exporting its advanced therapies to meet healthcare needs across different markets. With a robust pipeline of new products and significant investment in research and development, Merck plays a vital role in advancing medical breakthroughs and enhancing patient care. Beyond pharmaceuticals, Merck is involved in animal health, providing veterinary vaccines and services, contributing to agricultural productivity and food security. The company's ongoing efforts in groundbreaking research and public health initiatives underscore its importance in the healthcare sector.
Official SEC Documents
Advertisement